Search

Displaying results 4871 - 4880 of 10000 in total
  1. Drug

    NV-52

    go.drugbank.com/drugs/DB05673
    Experimental

    NV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.

  2. Drug

    Alicaforsen

    go.drugbank.com/drugs/DB06224
    Investigational

  3. Drug

    Sitamaquine

    go.drugbank.com/drugs/DB04909
    Investigational

    Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential

  4. Drug

    Taberminogene vadenovec

    go.drugbank.com/drugs/DB05011
    Experimental

    EG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it has received approval from the US Recombinant DNA Advisory Committee (RAC). … Taberminogene vadenovec (EG004) is a novel product consisting of a local delivery device and a gene-based medicine, being developed to prevent the blocking of veins and arteries that frequently occurs

  5. Drug

    Ceftezole

    go.drugbank.com/drugs/DB13821
    Investigational

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Cefbuperazone

    go.drugbank.com/drugs/DB13638
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Cefatrizine

    go.drugbank.com/drugs/DB13266
    Investigational

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Niflumic acid

    go.drugbank.com/drugs/DB04552
    Investigational

    Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.

    Categories: Antiinflammatory Preparations, Non-Steroids for Topical Use
  9. Drug

    Vintafolide

    go.drugbank.com/drugs/DB05168
    Investigational

    Vintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.

  10. Drug

    DDP733

    go.drugbank.com/drugs/DB05049
    Investigational

    DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD). … It is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system.